La vendita allo scoperto per CG Oncology dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CG Oncology. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CG Oncology (NASDAQ:CGON) Azioni, Report sulle vendite allo scoperto

CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology Inc

Company's Rapid Alcohol-Reducing Beverage, Sure Shot, to be Sold in 192 Stores Across Nevada, Arizona, and California
JUPITER, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new agreement with a leading national grocery chain to sell its convenient, newly branded 4 oz. Sure Shot beverages in select stores across the Southwest. This chain boasts over 2,200 stores nationwide, making them a significant player in the grocery industry.
This strategic launch in 192 stores across Nevada, Arizona, and California represents a significant milestone in Safety Shot's growth strategy. It provides access to a substantial and rapidly growing alcohol beverage market and marks a key step towards the Company's goal of nationwide distribution.

News

SHOT

Safety Shot Announced A New Agreement With A Leading National Grocery Chain To Sell Its Convenient, Newly Branded 4 Oz. Sure Shot Beverages In Select Stores Across The Southwest

Evercore ISI Group analyst Duane Pfenningwerth downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Outperform to In-Line and maintains the price target from $10.5 to $10.5.

Downgrades

Price Target

Analyst Ratings

Evercore ISI Group Downgrades Diamondrock Hospitality to In-Line, Maintains Price Target to $10.5

WIIM

RVYL

Ryvyl shares are trading lower. HC Wainwright & Co. reiterated a Neutral rating on the stock.

<a href="https://www.globenewswire.com/Tracker?data=oitox4x61cysgmwWmH-4y0XEjZKDx7vc9SYpYpngH33pFS6I3IlY-q-LsjR9lIzyVSYOkq29dQRMXutaPBuvrmxtA0l3Px7d-VkLvq27Yf5vY5uqf3Do5mhfCjwAUgGo">SeaStar Medical Holding Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE&#x2122; to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.

SeaStar Medical Reaches Milestone Of 100th QUELIMMUNE Commercial Device As Shipments Begin To Its Third Hospital Customer

Lument Finance Trust shares are trading higher following a Q3 earnings beat.

SPPL

SIMPPLE shares are trading higher after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore's International Airport Terminal.

SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) reported quarterly losses of $(0.25) per share. This is a 74.75 percent increase over losses of $(0.99) per share from the same period last year. The company reported $881.69 thousand in sales this quarter. This is a 34.66 percent decrease over sales of $1.35 million the same period last year.

Earnings

SBET

SharpLink Gaming Q3 EPS $(0.25) Up From $(0.99) YoY, Sales $881.69K Down From $1.35M YoY

LIFW

MSP Recovery shares are trading lower. The company reported Q3 financial results.

BTOC

Armlogi Q1 Total Revenue $42.5M, Up 3% YoY; EPS $(0.11) vs $0.07 YoY

SharpLink Gaming Q3 Revenue $881.690K Down From $1.349M YoY

SIMPPLE Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) ("SIMPPLE" or "the Company"), a leading technology provider and innovator in the facilities management (FM) sector, today announced that the Company has been awarded a $400,000 contract for the supply of autonomous cleaning robotics at one of Singapore's international airport terminals.
This robot tender success comes as part of the airport's renewal program and complements the existing fleet of autonomous cleaning robots across its airport terminals, where the Company has been one of two incumbent robotic suppliers for the past five years.
The results of the ongoing tender exercise for the remaining airport terminals will be announced in the near future, with an expected aggregate contract value of $1.8 million.

Contracts

Global

SIMPPLE Wins $400,000 Contract To Supply Autonomous Cleaning Robots At Singapore's International Airport Terminal; The Results Of The Ongoing Tender Exercise For The Remaining Airport Terminals Will Be Announced In The Near Future, With An Expected Aggregate Contract Value Of $1.8M

PHIO

Phio Pharma shares are trading higher. The company reported Q3 financial results.

EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), the world's leading Urban Air Mobility ("UAM") technology platform company, today announced that it has signed a cooperation framework agreement ("Agreement") with Zhejiang Sunriver Culture and Tourism Co., Ltd. ("Sunriver", 600576.SH), a China A-share listed company, to explore an industrial model that integrates low-altitude economy with cultural tourism in China. Under the Agreement, Sunriver plans to purchase 50 units of EH216-S or similar pilotless passenger-carrying aircraft from EHang for its cultural tourism projects based on market development needs. Sunriver has placed a purchase order for 5 units of EH216-S as the first batch for aerial tourism use cases. The remaining aircraft will be gradually deployed in the tourism attractions under the Sunriver.

EHang Partners with Sunriver To Expand Chinese Cultural Tourism Market With Purchase Plan For 50 Units Of EH216-S Or Similar Pilotless Passenger-Carrying Aircraft From EHang For Its Cultural Tourism Projects Based On Market Development Needs

Suburban Propane Partners, L.P. (NYSE:<a href="https://www.benzinga.com/stock/SPH#NYSE">SPH</a>), a nationwide distributor of propane, renewable propane, renewable natural gas, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, announced today an executive promotion in line with its planned management succession. As previously announced, Steven C. Boyd, the Partnership's Chief Operating Officer, will retire effective January 1, 2025.
The Partnership announced that Alejandro ("Alex") Centeno has been promoted to Senior Vice President – Operations as successor to Mr. Boyd. In his role, Mr.&nbsp;Centeno will report to Michael A. Stivala, President and Chief Executive Officer. Mr.&nbsp;Centeno has been with the Partnership for over 15 years, where he has held several managerial positions within the operations, most recently, rising to the level of Vice President – Operations since August 2023. In his new position, Mr.&nbsp;Centeno will be responsible for leading all aspects of the day-to-day operations of the propane business, as well as advancing the Partnership's customer base growth and retention initiatives, driving continued improvements in operational efficiencies and overseeing operational support functions; including safety, marketing and fleet management.&nbsp;

Management

Suburban Propane Partners, L.P.'s Steven C. Boyd, The Partnership's Chief Operating Officer, Will Retire Effective January 1, 2025; Alejandro ("Alex") Centeno Has Been Promoted To Senior Vice President – Operations As Successor To Mr. Boyd

Benchmark analyst Daniel Kurnos maintains Cineverse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>) with a Speculative Buy and raises the price target from $9 to $10.

CNVS

Benchmark Maintains Speculative Buy on Cineverse, Raises Price Target to $10

AKAM

Akamai Is The Winning Bidder To Acquire Select Assets From Edgio, Including Customer Contracts From Edgio's Businesses In Security And Content Delivery, And Non-Exclusive License Rights To Edgio's Entire Patent Portfolio

IFRX

InflaRx shares are trading higher after the company announced CHMP of the European Medicines Agency recommended the marketing authorization of Gohibic for the treatment of adult patients with Sars-cov-2-inducted acute respiratory distress syndrome.

Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) reported quarterly losses of $(1.29) per share. This is a 78.36 percent increase over losses of $(5.96) per share from the same period last year. The company reported $7.53 million in sales this quarter. This is a 29.81 percent increase over sales of $5.80 million the same period last year.

SLNH

Soluna Holdings Q3 EPS $(1.29) Up From $(5.96) YoY, Sales $7.53M Up From $5.80M YoY

MAMO

Massimo Group Q3 EPS $(0.06) Down From $(0.10) YoY; Revenue $25.6M Down From $29.9M YoY

Benchmark analyst Josh Sullivan maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Buy and raises the price target from $10 to $16.

LUNR

Benchmark Maintains Buy on Intuitive Machines, Raises Price Target to $16

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target ...

Buy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market Prospects

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associate...

Optimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene Prospects

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $86....

Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market Opportunities

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target...

Promising Prospects for CG Oncology, Inc.: Buy Rating Reinforced by Positive MIBC Treatment Outcomes and Market Opportunities

CG Oncology, Inc. GAAP EPS of -$0.30

CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors. CG...

CG Oncology's Financial Results and Clinical Developments

ALMS

AMGN

AZNCF

BMYMP

BPMC

CATX

CGEM

CGON

ELYM

GLAXF

HAFC

IDYA

IMCR

INCY

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

General

CADL

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Health Care

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

CG Oncology

Vendite allo scoperto

CG Oncology (NASDAQ:CGON) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO